Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02117479
Registration number
NCT02117479
Ethics application status
Date submitted
16/04/2014
Date registered
21/04/2014
Date last updated
26/03/2019
Titles & IDs
Public title
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Query!
Scientific title
A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)
Query!
Secondary ID [1]
0
0
INCB 18424-362
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pancreatic Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Pancreatic
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ruxolitinib
Treatment: Drugs - Placebo
Treatment: Drugs - Capecitabine
Experimental: Ruxolitinib plus capecitabine -
Active Comparator: Placebo plus capecitabine -
Treatment: Drugs: Ruxolitinib
5 mg tablets to be administered by mouth twice daily (BID)
Treatment: Drugs: Placebo
5 mg tablets to be administered by mouth twice daily (BID)
Treatment: Drugs: Capecitabine
150 and 500 mg tablets to be administered by mouth twice daily (BID)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall survival is reported here based on the number of deaths from randomization up to 6-months or to the data cutoff 11FEB2016.
Query!
Timepoint [1]
0
0
Randomization until death due to any cause; up to the data cutoff 11FEB2016.
Query!
Secondary outcome [1]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [1]
0
0
Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.
Query!
Timepoint [1]
0
0
Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Progression Free Survival (PFS)
Query!
Assessment method [2]
0
0
PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.
Query!
Timepoint [2]
0
0
Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.
Query!
Secondary outcome [3]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [3]
0
0
Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
Query!
Timepoint [3]
0
0
Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.
Query!
Secondary outcome [4]
0
0
Duration of Response
Query!
Assessment method [4]
0
0
Duration of overall response was defined as the time in months from Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) until the first date Progressive Disease (PD) was objectively documented or until the date of death.
Query!
Timepoint [4]
0
0
Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.
Query!
Secondary outcome [5]
0
0
Participants With Treatment-Emergent Adverse Events (TEAEs)
Query!
Assessment method [5]
0
0
A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug (ruxolitinib or placebo). A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).
Query!
Timepoint [5]
0
0
Baseline through approximately 30 days post treatment discontinuation; up to 6-months or to the data cutoff 11FEB2016.
Query!
Eligibility
Key inclusion criteria
- Histologically or cytologically confirmed adenocarcinoma of the pancreas.
- Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Received 1 prior chemotherapy regimen for advanced or metastatic disease (not
including neoadjuvant and/or adjuvant therapy).
- = 2 weeks elapsed from the completion of previous treatment regimen and participants
must have recovered or be at a new stable baseline from any related toxicities.
- Radiographically measurable or evaluable disease
- Modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:
1. mGPS of 1: C-reactive protein >10 mg/L and albumin =35 g/L
2. mGPS of 2: C-reactive protein >10 mg/L and albumin <35 g/L
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Received more than 1 prior regimen for advanced or metastatic disease.
- Ongoing radiation therapy, radiation therapy administered within 30 days of
enrollment.
- Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery,
immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor
embolization).
- Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase
deficiency (DPD), or other known hypersensitivity to active substances, including
fluorouracil (5-FU), or ruxolitinib, or any of their excipients.
- Prior treatment with a JAK inhibitor for any indication.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
321
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Australian Capital Territory
Query!
Recruitment hospital [2]
0
0
- New South Wales
Query!
Recruitment hospital [3]
0
0
- South Australia
Query!
Recruitment hospital [4]
0
0
- Victoria
Query!
Recruitment postcode(s) [1]
0
0
- Australian Capital Territory
Query!
Recruitment postcode(s) [2]
0
0
- New South Wales
Query!
Recruitment postcode(s) [3]
0
0
- South Australia
Query!
Recruitment postcode(s) [4]
0
0
- Victoria
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maine
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Maryland
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Massachusetts
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Michigan
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Minnesota
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Missouri
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Montana
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nebraska
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Nevada
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New Hampshire
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Jersey
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Mexico
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New York
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
North Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Ohio
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Oregon
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Pennsylvania
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
South Carolina
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Tennessee
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Texas
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Utah
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Virginia
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Washington
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Wisconsin
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Aalst
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Brugge
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Bruxelles
Query!
Country [41]
0
0
Belgium
Query!
State/province [41]
0
0
Edegem
Query!
Country [42]
0
0
Belgium
Query!
State/province [42]
0
0
Gent
Query!
Country [43]
0
0
Belgium
Query!
State/province [43]
0
0
Gilly
Query!
Country [44]
0
0
Belgium
Query!
State/province [44]
0
0
Kortrijk
Query!
Country [45]
0
0
Belgium
Query!
State/province [45]
0
0
Leuven
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Alberta
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Ontario
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Quebec
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Aschaffenburg
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Berlin
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Bochum
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Essen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Frankford
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Koeln
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Velbert
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Aviano
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Bari
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Bergamo
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Brescia
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Cremona
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Firenze
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Genova
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Lido di Camaiore
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Milano
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Napoli
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Pisa
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Rimini
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Roma
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Hwasun-gun
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Seongnam-si
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Seoul
Query!
Country [72]
0
0
New Zealand
Query!
State/province [72]
0
0
Auckland
Query!
Country [73]
0
0
New Zealand
Query!
State/province [73]
0
0
Christchurch
Query!
Country [74]
0
0
New Zealand
Query!
State/province [74]
0
0
Hamilton
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Badajoz
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Barcelona
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Madrid
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Malaga
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Seville
Query!
Country [80]
0
0
Taiwan
Query!
State/province [80]
0
0
Taichung
Query!
Country [81]
0
0
Taiwan
Query!
State/province [81]
0
0
Tainan
Query!
Country [82]
0
0
Taiwan
Query!
State/province [82]
0
0
Taipei
Query!
Country [83]
0
0
Thailand
Query!
State/province [83]
0
0
Patumwan
Query!
Country [84]
0
0
Thailand
Query!
State/province [84]
0
0
Ratchathewi
Query!
Country [85]
0
0
Thailand
Query!
State/province [85]
0
0
Seetatarom
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Aberdeen
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Bangor
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Birmingham
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Boston
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Bristol
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Cardiff
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
Glasgow
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Guildford
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Harlow
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Huddersfield
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Lancaster
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Leeds
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
London
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Manchester
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Newcastle upon Tyne
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Nottingham
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Plymouth
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Southampton
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Sutton
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Welwyn Garden City
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Incyte Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine
for the treatment of advanced or metastatic pancreatic cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02117479
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Fitzroy Dawkins, M.D.
Query!
Address
0
0
Incyte Corporation
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02117479
Download to PDF